Amneal Pharmaceuticals is trading at $18.62, down 4.3% in pre-market, with healthcare weakness a possible factor. - Shares closed at $19.45 on November 5, after several sessions of declines. - No fresh company-specific catalyst surfaced November 6; the November 3 earnings beat and raised outlook were positive and do not clearly explain the drop. - XLV was reported down about 1.25% pre-market as markets awaited the October jobs report.